Healthcare Industry News: proton
News Release - April 29, 2008
Neuromed Names Sean Cunliffe Chief Commercial OfficerCONSHOHOCKEN, PA and VANCOUVER, BC, April 29 (HSMN NewsFeed) - Neuromed Pharmaceuticals, a biopharmaceutical company developing new and improved chronic pain drugs, today announced the promotion of Sean Cunliffe to Chief Commercial Officer. Mr. Cunliffe will lead all pre- and post-approval commercial activities of Neuromed's product candidates, including NMED-1077 (OROS® Hydromorphone) in Phase 3 clinical development for the treatment of moderate-to-severe chronic pain.
"Sean has had exceptional commercial success in his 25 years in the pharmaceutical industry and since joining Neuromed, he has been instrumental in negotiating the partnership agreement with Merck and acquiring the U.S. marketing rights to NMED-1077 from ALZA Corporation," said Dr. Christopher Gallen, President & CEO. "Sean will continue to build Neuromed's commercial infrastructure as we prepare for the anticipated U.S. launch of NMED-1077."
Mr. Sean Cunliffe joined Neuromed in 2005 as Vice President of Commercial Development. He has broad commercial expertise and has led the marketing efforts of many major brands including Effexor®, protonix®, Altace®, Valtrex®, Zantac®, Flovent®, Flonase®, Serevent®, Beclovent®, Cordarone®, Lotronex®, Epivir HBV® and Ventolin®. Prior to joining Neuromed, Mr. Cunliffe was Vice President, New Product Marketing at Wyeth where he co-chaired, along with Discovery, both the Neuroscience and Cardiovascular leadership teams. Other positions at Wyeth included Vice President Neuroscience Marketing and Vice President Cardiovascular and Gastrointestinal Marketing. In addition, Mr. Cunliffe held positions with Glaxo and Astra Pharmaceuticals in a variety of sales and marketing roles. Mr. Cunliffe received his M.B.A. in Finance from McMaster University in Hamilton, Ontario and an Honours B.Sc. in Biology from Queen's University in Kingston, Ontario.
Neuromed is a privately held biopharmaceutical company in business to develop new and improved pain medicines. We have three programs aimed at addressing this important unmet medical need. Our lead product, NMED-1077 (OROS® Hydromorphone), is an extended release formulation of hydromorphone in Phase 3 clinical development. Neuromed is also developing oral drug candidates to block N-type calcium channels, a new and important target directly involved in pain signaling. Our third program is focused on producing promising T-type calcium channel blockers aimed at treating pain, epilepsy and hypertension. For more information visit www.neuromed.com.
OROS® is a trademark of ALZA Corporation; EFFEXOR® and protonIX® are trademarks of Wyeth Pharmaceuticals; ALTACE® is a trademark of King Pharmaceuticals, VALTREX®, ZANTAC®, FLOVENT®, FLONASE®, SEREVENT® and BECLOVENT®, EPIVIR HBV® and VENTOLIN® are trademarks of GlaxoSmithKline, Inc.; LOTRONEX® is a trademark of Glaxo Wellcome Group of Companies; CORDARONE®, is a trademark of Sanofi-Synthelabo.
Neuromed cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Neuromed's forward-looking statements due to the risks and uncertainties inherent in Neuromed's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization, or that could result in recalls or product liability claims; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Neuromed does not assume any obligation to update any forward-looking statements.
Source: Neuromed Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.